Navigation Links
Diagnoplex Closes CHF10 Million ($8.3 Million) Series A Financing
Date:12/10/2008

LAUSANNE, Switzerland, December 10 /PRNewswire/ -- Diagnoplex, a developer of molecular cancer diagnostics today announced the closing of a Series A financing raising CHF10 million ($8.3 million). The A-round was led by Novartis Venture Fund and NeoMed, with Initiative Capital Romandie acting as co-investor. The Novartis Venture Fund was also a seed investor in the company. BCCC Avocats acted as counsel to the investors and BMP Associés acted as counsel to the company.

In connection with the financing, Anja König, Ph.D., a Managing Director of Novartis Venture Fund, and Thomas Goebel, Ph.D., a Principal at NeoMed, will join Diagnoplex' board of directors, while Claude Suard, Partner at DEFI Gestion, will join the board as an observer.

Diagnoplex technology platform

Leveraging its unique and proprietary molecular platform capabilities, Diagnoplex develops blood-based cancer diagnostics. Diagnoplex' single-channel quantitative multiplex reverse transcriptase-polymerase chain reaction (scqmRT-PCR) yields the quantification of copy number obtained with real-time PCR, and allows quantifying up to 60 genes simultaneously. The scqmRT-PCR platform offers several important competitive advantages. It pairs the high accuracy and reliability of PCR with the possibility to read out multi-gene signatures of different cancers. As opposed to microarray platforms, it is easily scalable and can be run in most standard testing laboratories. Stavros Therianos, PhD, founder and chief executive officer of Diagnoplex, developed the platform during his tenure at Rochester University, NY.

Diagnoplex lead product - Colox

Diagnoplex will use the proceeds from the financing to support the further clinical development of its lead product Colox, a non-invasive test for the early detection of colon cancer, which will be made available as a ready-to-use clinical laboratory kit. Early result
'/>"/>

SOURCE Diagnoplex
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
2. Genmab Discloses Target and Development Plans for HuMax-Inflam
3. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
4. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
5. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. BioVex Closes Second Round of Series E Financing
8. Pharmaxis Closes Share Purchase Plan
9. The closest look ever at native human tissue
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... 2014 Deep Knowledge Ventures last ... on ‘Commercialising Longevity Research’ and welcomed a host ... London Bioscience Innovation Center for the event, organised ... Analytics Ltd. The meeting highlighted the need for ... for age-related disease, as well as the crucial ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... recommend Corvalen(R) D-Ribose to boost cellular energy, NEW YORK, ... you,could sleep all year and not catch up? That,s how ... there was a good reason to be,exhausted -- five boys ... fix., Then came a sixth son, and she began ...
... System Combines Clinical Benefits of Dual Wavelengths Through ... Time While Providing a Uniform, Safe and Effective ... Treatment - New Offering Signals Company,s Expansion into International Laser ... Lipolysis Market, WESTFORD, Mass., April 28 Cynosure, ...
... Calif., April 28 Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: ... its Phase 2 testing results of Rh-Apo2L and,expects to ... announced that the target cancers for the drug have ... targets,that the Company has chosen are ailments which Rh-Apo2L ...
Cached Biology Technology:D-Ribose Helps Energy-Starved Hearts 2Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM) 2Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM) 3Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM) 4Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM) 5Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing 2
(Date:7/11/2014)... OAK RIDGE, Tenn., July 11, 2014--Researchers at the ... received eight R&D 100 awards, presented by R&D ... innovations. , "These awards recognize the tremendous ... Energy Ernest Moniz. "Research and development at the ... its energy challenges and pursue the scientific and ...
(Date:7/11/2014)... near the City of Entiat on Tuesday, July 8, ... quickly grew to over 1,000 acres by evening. Three ... under investigation by the Washington Department of Natural Resources. ... resources in developing fire control strategies and tactics. Other ... Department of Natural Resources, (WA DNR), Bureau of Land ...
(Date:7/11/2014)... is creating a new professorship in tissue engineering ... for Molecular Engineering and the Marine Biological Laboratory, ... Millicent and Eugene Bell Foundation., The Eugene Bell ... Institute for Molecular Engineering. That endowed chair holder ... MBL,s Eugene Bell Center for Regenerative Biology and ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New professorship in tissue engineering links molecular engineering, marine biology 2
... the atmosphere through summer thunderstorm clouds, according to a ... Letters . How much the warming effect of these ... not yet clear. To find out, researchers need to ... Pollution strengthens thunderstorm clouds, causing their anvil-shaped tops ...
... rate at which the rabies virus evolves in bats may ... to researchers at the University of Georgia, the U.S. Centers ... Belgium. Their study, published May 17 in the journal ... the most accurate predictor of the viral rate of evolution. ...
... physicists and University of Miami biologists addresses an ... do living cells figure out when and where ... Dimitrios Vavylonis and Associate Professor Fulvia Verde discovered ... a ballet of proteins that change its polarity. ...
Cached Biology News:Pollution teams with thunderclouds to warm atmosphere 2Pollution teams with thunderclouds to warm atmosphere 3Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats 2Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats 3A cell's first steps: Building a model to explain how cells grow 2
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Request Info...
... Alkaline Phosphatase, Calf Intestinal (CIAP), catalyzes the ... and ribo- and deoxyribonucleoside triphosphates. This enzyme ... of linearized cloning vector DNA by removing ... also be used for the dephosphorylation of ...
100 adhesive strips....
Biology Products: